Skip to content

Horizon Discovery

Pharmaceuticals & Biotechnology
Exit type:
Placement of blocks of shares on AIM
Most Recent ExitIn Price/ShareAverage Out Price/Share
  2016 £0.87 £1.59

Horizon Discovery is a world leader in the application of gene editing technologies, which are used for research into, and treatment of, genetically-based diseases.

Calculus Capital exited its holding in 2016, via a placement of shares on the AIM. The average exit multiple for sale of the shares was 1.82x, constituting a tax free return of over 160%, when factoring in initial investor income tax relief of 30%. The investment was held for 3 years, 3 months.

Past performance is not a guide to future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future.